Shanghai Jinhe Bio-Pharmaceutical Co., Ltd.

On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Shanghai Jinhe BIO-PHARMACEUTICAL Co., Ltd.

22 YRS

Shanghai, China

CNY 3.4 Million

19980 m²

100-500 people

Main Products: Paclitaxel / Docetaxel / Docetaxel Trihydrate / Cabazitaxel / 10-Deacetylbaccatin III / Baccatine III

Shanghai, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

VERIFIEDMANUFACTURINGCOMPANY

Business Type

Manufacturing

Total Employees

100-500 People

Plant Size

30 Acres

Production Experience

22+ Years

Registered Capital

CNY 3.4 Million

MAIN
PRODUCTS

1/3

Paclitaxel (Natural) USP34

CAS: 33069-62-4

Packing: 5 KG/BOTTLE

Lead Time: 14-30 days

Inquiry

1/3

Docetaxel Anhydrous 99.5%

CAS: 114977-28-5

Packing: 5 KG/BOTTLE

Lead Time: 14-30 days

Inquiry

1/3

Docetaxel Trihydrate

CAS: 148408-66-6

Packing: 5 KG/BOTTLE

Lead Time: 14-30 days

Inquiry

ABOUT US

Shanghai Jinhe BIO-PHARMACEUTICAL Co., Ltd.

Shanghai Jinhe bio-pharmaceutical Co., Ltd. is a pharmaceutical enterprise specializing in the research, production and sales of antitumor APIs and intermediates. Founded in March 2002, based on the scientific research achievements of Fudan University, the company began to undertake the international paclitaxel API processing business. After several years of hard work, the company has successfully developed paclitaxel, docetaxel, irinotecan, etoposide and other products, from naturally extracted antitumor drugs to plant-derived antitumor drug raw materials. In the past two years, the company has developed carbataxel, palonosetron hydrochloride and other products. In 2012, the company signed a contract with Shanghai Zhongxi Sanwei Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceutical Group. Since then, Jinhe biology has been positioned as the production base of antitumor API of Shanghai Pharmaceutical Group. In 2015, the company and Shanghai Huayu Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shanghai pharmaceutical, invested in the reorganization of Dali Zhonggu yew biological Co., Ltd. (now renamed Shanghai Pharmaceutical Group (DALI) yew biological Co., Ltd.) in cash to integrate Shanghai Pharmaceutical antitumor drug industry chain and establish API advantages. In January 2017, the company successfully passed the GMP certification of API (paclitaxel, docetaxel). Jinhe has always been committed to being a responsible and responsible pharmaceutical enterprise with leading position in China, significant international influence and responsibility.